Drug Trial Radar · NCT00135707
Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)
Last checked: Nov 19, 2026Latest source record: Feb 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10,154
Actual
Start
Jun 2003
Primary completion
Oct 2008
Study completion Jan 2009
Sponsor
- Lead sponsor
- The George Washington University Biostatistics CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- First posted
- Aug 26, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- Who can join
- Female only
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Preeclampsia is one of the most common complications of pregnancy and is characterized by high blood pressure and protein in the urine. This can cause problems in the second half of pregnancy for both the mother and fetus. This study of preeclampsia consists of two parts: 1) a randomized, placebo controlled, multicenter clinical trial of 10,000 low-risk nulliparous women between 9 and 16 weeks gestation and 2) an observational, cohort study of 4,000 patients between 9 and 12 weeks gestation who are also enrolled in the trial. Subjects in both parts will receive either 1000 mg of vitamin C and 400 IU of vitamin E or matching placebo daily. The purpose of the randomized, clinical trial is to find out if high doses of vitamin C and E will reduce the risk of preeclampsia and other problems associated with the disease. The study will also evaluate the safety of antioxidant therapy for mother and infant. Patients will be seen monthly to receive their supply of study drug, to have weight and blood pressure recorded, to have urine protein measured, and to assess any side effects. At two visits, blood and urine will be collected. The observational, cohort study will prospectively measure potential biochemical and biophysical markers that might predict preeclampsia. These patients will have additional procedures including uterine artery Doppler and blood drawn for a complete blood count (CBC).
Conditions
- Preeclampsia
Interventions
Dietary Supplement/VitaminsDrug
Vitamin C (1000 mg) and Vitamin E (400 IU) per capsule, two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.
Placebo for Vitamin C and Vitamin EDrug
Placebo two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of Pregnancy-associated Hypertension and Serious Adverse Outcomes in the Mother or Fetus or NeonateTime frame: 20 weeks through discharge following delivery
- Severe HypertensionTime frame: 20 weeks through discharge following delivery
- Severe or Mild Pregnancy-associated Hypertension With Elevated Liver Enzyme LevelsTime frame: 20 weeks through discharge following delivery
- Severe or Mild Pregnancy-associated Hypertension With ThrombocytopeniaTime frame: 20 weeks through discharge following delivery
- Severe or Mild Pregnancy-associated Hypertension With an Elevated Serum Creatinine LevelTime frame: 20 weeks through discharge following delivery
- Severe or Mild Pregnancy-associated Hypertension With an Eclamptic SeizureTime frame: 20 weeks through discharge following delivery
- Severe or Mild Pregnancy-associated Hypertension With an Indicated Preterm Birth Before 32 Weeks of Gestation Owing to Hypertension-related DisordersTime frame: 20 weeks through discharge following delivery
- Severe or Mild Pregnancy-associated Hypertension With a Fetus That Was Small for Gestational Age (Below the 3rd Percentile) Adjusted for Sex and Race or Ethnic GroupTime frame: 20 weeks through discharge following delivery
- Severe or Mild Pregnancy-associated Hypertension With a Fetal Death After 20 Weeks of Gestation or Neonatal DeathTime frame: 20 weeks through discharge or prior to discharge following delivery admission
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama - Birmingham
Birmingham, Alabama
Northwestern University
Chicago, Illinois
Wayne State University
Detroit, Michigan
Columbia University
New York, New York
University of North Carolina - Chapel Hill
Chapel Hill, North Carolina
Wake Forest University School of Medicine
Winston-Salem, North Carolina
Case Western University
Cleveland, Ohio
Ohio State University
Columbus, Ohio
Oregon Health and Sciences University
Portland, Oregon
Drexel University
Philadelphia, Pennsylvania
University of Pittsburgh Magee Womens Hospital
Pittsburgh, Pennsylvania
Brown University
Providence, Rhode Island
University of Texas - Southwest
Dallas, Texas
University of Texas Medical Branch
Galveston, Texas
University of Texas - Houston
Houston, Texas
University of Utah Medical Center
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.